A Phase II proof-of-concept trial to study kinase inhibition in relapsed/refracto

研究复发/难治患者激酶抑制作用的 II 期概念验证试验

• 批准号: 8234975
• 负责人: MARC Maurice LORIAUX
• 金额: $ 27.27万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-03-02 至 2016-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8234975
• 关键词: Acute leukemia; Address; Biological Assay; Biological Markers; Biopsy; Blast Cell; Bone Marrow; Cell Survival; Clinical; Clinical Trials; Correlative Study; Data; Development; Drug Combinations; Effectiveness; Enrollment; FDA approved; Future; Gene Targeting; Genetic Predisposition to Disease; Genomics; Goals; In Vitro; In complete remission; Individual; International; Lesion; Malignant Neoplasms; Marrow; Molecular Abnormality; Molecular Profiling; Molecular Target; Monitor; Outcome; Pathogenesis; Pathway interactions; Patients; Pharmaceutical Preparations; Phase; Phosphotransferases; Pilot Projects; Play; Progression-Free Survivals; Protein Tyrosine Kinase; Refractory; Relapse; Role; Sampling; Signal Pathway; Testing; Therapeutic; Time; arm; base; cancer cell; chemotherapy; clinically relevant; drug efficacy; drug sensitivity; effective therapy; improved; inclusion criteria; inhibitor/antagonist; kinase inhibitor; leukemia; leukemogenesis; next generation; older patient; outcome forecast; partial response; pilot trial; pre-clinical; public health relevance; response; small molecule; therapeutic target; working group

DESCRIPTION (provided by applicant): Patients with relapsed or refractory acute leukemias and elderly patients with previously untreated acute leukemia who are unfit for standard induction have a dismal prognosis with conventional chemotherapy. The development of more effective and less toxic therapies will require the identification of the molecular abnormalities contributing to leukemogenesis and the identification of drugs that specifically block the activity of these lesions. We hypothesize that aberrantly activated tyrosine kinase signaling pathways play a critical role in the pathogenesis of acute leukemia, and our preliminary data suggest that the molecular abnormalities causing aberrant kinase activation are unique in a significant number of patients. Thus, effective therapies for acute leukemia will need to be determined on an individual patient basis. To address this need, we have developed a small-molecule kinase inhibitor assay that can identify therapeutic targets in tyrosine kinase signaling pathways in primary acute leukemia samples and provide individualized therapeutic options in a clinically relevant time frame. The primary goals of the proposed project will be to validate the role of our pre- clinical kinase inhibitor screen in predicting effective individualized therapies and to explore the molecular abnormalities underlying drug sensitivity. Accordingly, the first aim is to evaluate the efficacy of an in-vitro inhibitor sensitivity assay for prediction of clinically effective individualized/targeted therapies for acute leukemia patients in a single-arm phase II pilot trial enrolling 24 patients. Inclusion criteria will be limited to relapsed/refractory acute leukemia patients as well as elderly patients not eligible for conventional chemotherapy with in vitro sensitivity to one or more drugs in the inhibitor assay. The primary objective is to determine the clinical activity, defined as > 25% decrease in bone marrow blast counts at 28 days after initiation of therapy. The second aim is to rapidly identify the genetic etiology underlying aberrantly activated tyrosine kinase pathways in leukemia samples from individual patients. The small molecule kinase inhibitor assay will be used to identify activated kinase pathways that are crucial for malignant cell viability in individual samples, and the mechanism of activation will be explored using high-throughput sequence and expression profiling. By utilizing our pre-clinical assay to select individualized leukemia therapies, we hope to create a platform upon which we can rapidly test the effectiveness of individualized kinase therapy and apply this information to enhance development of new drugs and new drug combinations in leukemia patients. It is also our hope to establish a paradigm in which patient-tailored therapies can be offered to all patients with cancer. PUBLIC HEALTH RELEVANCE: The development of more effective and less toxic therapies for acute leukemia will require identification of the causative molecular abnormalities and identification of drugs that specifically block the activity of these abnormalities. We hypothesize that these abnormalities are unique in many leukemia patients and that these patients will require individualized therapies to target their unique lesions. Our proposed clinical trial that integrates molecular target identification with individualized treatment will help to establish a paradigm where cancers are defined by molecular targets and patients are matched with specific targeted therapies to yield improved therapeutic outcomes.

描述(由申请人提供)：复发或难治性急性白血病患者和以前未经治疗的急性白血病的老年患者不适合标准诱导，用传统化疗预后很差。开发更有效和毒性更低的治疗方法将需要确定导致白血病发生的分子异常，并确定专门阻断这些损害活动的药物。我们假设异常激活的酪氨酸激酶信号通路在急性白血病的发病机制中起关键作用，我们的初步数据表明，导致异常激活的分子异常在相当数量的患者中是独一无二的。因此，急性白血病的有效治疗方法需要根据患者的具体情况而定。为了满足这一需求，我们开发了一种小分子激酶抑制剂试验，可以在原发急性白血病样本中识别酪氨酸激酶信号通路的治疗靶点，并在临床相关的时间框架内提供个性化的治疗选择。拟议项目的主要目标将是验证我们的临床前激酶抑制剂筛查在预测有效的个体化治疗方面的作用，并探索药物敏感性背后的分子异常。因此，第一个目标是评估体外抑制物敏感性分析在单臂II期试点试验中预测急性白血病患者临床有效个体化/靶向治疗的有效性，该试验招募了24名患者。纳入标准将限于复发/难治性急性白血病患者以及在抑制试验中对一种或多种药物体外敏感而不符合常规化疗条件的老年患者。主要目的是确定临床活动性，定义为治疗开始后28天骨髓原始细胞计数下降25%。第二个目标是快速确定个体患者白血病样本中异常激活的酪氨酸激酶通路的遗传病因。小分子激酶抑制试验将被用来在单个样本中识别对恶性细胞生存至关重要的激活激酶通路，并将使用高通量序列和表达谱来探索激活机制。通过利用我们的临床前试验来选择个性化的白血病治疗方法，我们希望创建一个平台，在这个平台上我们可以快速测试个性化激酶治疗的有效性，并将这些信息应用于促进白血病患者的新药和新药组合的开发。我们也希望建立一种模式，在这种模式下，可以为所有癌症患者提供患者定制的治疗方法。 公共卫生相关性：开发更有效和毒性更低的急性白血病治疗方法，将需要确定导致分子异常的原因，并确定专门阻断这些异常活动的药物。我们假设这些异常在许多白血病患者中是独一无二的，这些患者将需要个性化的治疗来针对他们独特的皮损。我们提议的将分子靶标识别与个体化治疗相结合的临床试验将有助于建立一种范式，其中癌症由分子靶标定义，患者与特定的靶向治疗相匹配，以产生更好的治疗结果。